Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ixazomib for prevention of acute graft-versus-host disease after allogeneic stem cell transplantation
MOH_2021-09-21_010266Phase 2Not yet recruiting
- Sponsor
- ד"ר ליאת שרגיאן
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixazomib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by ד"ר ליאת שרגיאן. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
ixazomib
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on MOH_2021-09-21_010266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-09-21_010266.